Calc Function

  • Diagnosis
  • Rule Out
  • Prognosis
  • Formula
  • Treatment
  • Algorithm
  • CME Options
    CME Calcs
    Disease
    Select...
    Specialty
    Select...
    Chief Complaint
    Select...
    Organ System
    Select...

    Role of Bone-modifying Agents in Multiple Myeloma(beta)

    Based on guidelines from the American Society of Clinical Oncology.

    Indications

    Patients with Lytic Disease

    N/A
    export-img

    Patients with Osteopenia in the Absence of Lytic Disease

    N/A
    export-img

    Adjunct to Pain Control

    N/A
    export-img

    Patients with Myeloma with Normal Plain Radiograph or Osteopenia in Bone Mineral Density Measurements

    N/A
    export-img

    Patients with Monoclonal Gammopathy of Undetermined Significance

    N/A
    export-img

    Dosing and Selection

    N/A
    export-img

    N/A
    export-img

    Duration

    N/A
    export-img

    Monitoring

    N/A
    export-img

    N/A
    export-img

    N/A
    export-img

    N/A
    export-img

    N/A
    export-img

    Biochemical Markers

    N/A
    export-img

    Osteonecrosis of the Jaw

    N/A
    export-img

    How strong is the ASCO's recommendation?

    N/A
    No recommendation was assigned.
    No evidence was assigned.

    Anderson K, Ismaila N, Flynn PJ, et al. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(8):812-818.